Daewoong Pharmaceutical will unveil its overseas expansion strategy and a roadmap for the development of new drugs at the JP Morgan Healthcare Conference in San Francisco on Jan. 15 (local time), the company announced on Jan. 9.
The JP Morgan Healthcare Conference is the world's most prestigious pharmaceutical and biotech conference, which takes place in the United States from Jan. 13 to 16 (local time).
Daewoong Pharmaceutical president Jeon Seung-ho and executives in charge of research and global business will attend the conference. Jeon will present the company’s global strategy and R&D vision at the emerging market track, a session that introduces fast-growing companies in emerging countries.
Jeon plans to share Daewoong’s R&D strategy, including major new drug development status and plans in 2020, as well as a joint venture agreement with Avacta of the United Kingdom on development of new immune disease treatments.
In particular, he will introduce strategies to advance into treatment market in developed countries, focusing on Nabota, the first Korean botulinum toxin to debut in the United States, Europe and Canada.
Daewoong is planning to present a detailed roadmap for the global clinical trial of Fexuprazan, a next-generation gastroesophageal reflux disease medicine that targets the 40 trillion won global market. Daewoong has submitted an application for a product license on Fexuprazan to the Korea Food and Drug Administration after completing phase 3 domestic clinical trial in 2019, and is set to conduct global clinical trials in major markets this year.
The company will also present its innovative drug pipeline, including DWP212525, a medicine for autoimmune disorder, and DWN12088, a treatment for idiopathic pulmonary fibrosis disease, which are being developed as the world’s first-in-class drugs.